Feature

Biologic Fights Drive PTAB Drug Challenges To Record High

By Matthew Bultman (February 8, 2018, 9:56 PM EST) -- The number of challenges to drug patents at the Patent Trial and Appeal Board climbed to a record high in 2017, bolstered by an increasing number of petitions targeting patents covering biologics like the mega-blockbuster breast cancer drug Herceptin.

There were 211 petitions filed with the PTAB seeking America Invents Act review of biopharma patents last year, up from 179 in 2016 and 188 the year before, according to a recent report from Fish & Richardson PC.

The uptick in filings was driven, at least in part, by a rise in the number of challenges to patents for biologic drugs. There...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!